查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1573068

支氣管痙攣治療藥物市場：按治療類型、給藥途徑和最終用戶分類 - 全球預測 2025-2030

Bronchial Spasms Treatment Market by Treatment Type (Medications, Non-Pharmacological Treatments), Route of Administration (Inhalation, Intravenous, Oral), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年支氣管痙攣治療藥物市值為2.9681億美元，預計到2024年將達到3.0972億美元，複合年成長率為4.38%，預計到2030年將達到4.0777億美元。

支氣管痙攣治療市場包括各種旨在緩解氣喘和慢性阻塞性肺病（COPD）等氣道狹窄特徵的解決方案。治療選擇範圍從藥物干預（如支氣管擴張劑和皮質類固醇）到新的生物製藥和潛在的綜合療法。由於空氣污染、吸菸習慣和遺傳易感性等因素，全球呼吸系統疾病的盛行率不斷增加，對這些治療的需求也隨之增加。支氣管痙攣治療的應用對於預防醫學和急性加重的治療以改善患者的生活品質都很重要。最終使用場所包括醫院、診所和門診診所，而攜帶式吸入設備的進步也使家庭治療變得流行。市場的關鍵成長要素包括給藥系統的技術創新、支持性醫療保健政策以及新興國家醫療保健基礎設施的擴張。個人化醫療方法和針對支氣管痙攣特定途徑的新型治療方法的開發存在巨大的潛在機會。然而，高昂的研發成本、嚴格的監管要求以及學名藥的廣泛使用給品牌藥收益帶來壓力，給市場成長帶來挑戰。此外，複雜的治療方法導致的患者依從性問題也是一個障礙。為了利用成長，公司可以在數位健康解決方案等領域進行創新，透過提醒和即時監控來提高患者的依從性，或投資於更有效的吸入機制的研發。與高科技公司的合作可以增強治療的個人化以及對患者反應模式的資料驅動洞察。儘管競爭激烈，但我們對負擔得起且易於獲得的治療方法的關注，以及專注於研發和分銷的戰略夥伴關係關係，提供了持續的競爭優勢並推動市場擴張。

主要市場統計
基準年[2023] 2.9681億美元
預測年份 [2024] 30972萬美元
預測年份 [2030] 40077萬美元
複合年成長率（%） 4.38%

市場動態：快速發展的支氣管痙攣治療市場的關鍵市場洞察

供需的動態交互作用正在改變支氣管痙攣治療市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球氣喘和慢性阻塞性肺病盛行率上升
    • 增加政府支出和醫療保健工作
    • 提高對支氣管痙攣及其對健康影響的認知
  • 市場限制因素
    • 治療費用高昂以及藥品銷售的嚴格規定
  • 市場機會
    • 製藥公司與研究機構之間的策略聯盟
    • 吸入裝置、霧化器和支氣管痙攣治療的創新
  • 市場挑戰
    • 與支氣管痙攣治療相關的副作用

波特的五力：駕馭支氣管痙攣藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解支氣管痙攣治療市場的外部影響

外部宏觀環境因素在塑造支氣管痙攣治療藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解支氣管痙攣治療藥物市場的競爭狀況

支氣管痙攣治療藥物市場的詳細市場佔有率分析可以對供應商的業績進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣支氣管痙攣治療市場供應商的績效評估

FPNV 定位矩陣是評估支氣管痙攣治療藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪支氣管痙攣治療藥物市場的成功之路

對於希望加強在全球市場的影響力的公司來說，對支氣管痙攣治療藥物市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球氣喘和慢性阻塞性肺病盛行率上升
      • 擴大政府支出和醫療保健措施
      • 提高對支氣管痙攣及其對健康影響的認知
    • 抑制因素
      • 治療費用高，藥物釋放監管嚴格
    • 機會
      • 製藥公司與研究機構的策略夥伴關係
      • 吸入器、霧化器和支氣管痙攣治療的創新
    • 任務
      • 與支氣管痙攣治療相關的副作用
  • 市場區隔分析
    • 治療類型：用於即時緩解和長期管理的藥物的使用正在增加，以改善患者的生活品質。
    • 最終用戶：由於方便且易於維護而更喜歡居家照護環境的消費者。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依治療類型分類的支氣管痙攣治療藥物市場

  • 藥品
    • 支氣管擴張劑
    • 皮質類固醇
    • 白三烯調節劑
    • 肥大細胞穩定劑
    • 甲基黃嘌呤類
  • 非藥物治療
    • 氧氣療法
    • 呼吸復健

第7章支氣管痙攣治療藥物市場：依給藥途徑

  • 吸入
  • 靜脈
  • 口服
  • 皮下的

第8章支氣管痙攣治療藥物市場：依最終使用者分類

  • 門診手術中心
  • 家庭護理設置
  • 醫院/診所
  • 研究/學術機構

第9章北美和南美支氣管痙攣治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太支氣管痙攣治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲支氣管痙攣治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Verona Pharma 的 Otuvaile 獲得 FDA核准，成為首個新型吸入性 COPD 治療藥物
    • Viatris 和 Quindeva 推出了 Breyna，這是 FDA核准的非專利Symbicort，以改善氣喘和慢性阻塞性肺病的治療機會。
  • 戰略分析和建議
Product Code: MRR-3204321AF1B0

The Bronchial Spasms Treatment Market was valued at USD 296.81 million in 2023, expected to reach USD 309.72 million in 2024, and is projected to grow at a CAGR of 4.38%, to USD 400.77 million by 2030.

The market for bronchial spasms treatment encompasses a variety of solutions aimed at alleviating the constriction of airways characteristic of conditions such as asthma and chronic obstructive pulmonary disease (COPD). Treatment options range from pharmaceutical interventions-like bronchodilators and corticosteroids-to emerging biologics and possible integrative therapies. The necessity of these treatments is heightened by the increasing global prevalence of respiratory ailments due to factors such as air pollution, smoking habits, and genetic predispositions. Applications of bronchial spasm treatments are critical for both preventative care and the management of acute exacerbations to improve patient quality of life. End-use settings include hospitals, clinics, and outpatient services, while home-based treatments also gain traction with advancements in portable inhalation devices. Key growth influencers in the market include technological innovations in drug delivery systems, supportive healthcare policies, and the growing healthcare infrastructure in emerging economies. Significant potential opportunities lie in personalized medicine approaches and the development of novel therapies targeting specific pathways involved in bronchial spasms. However, market growth is challenged by high R&D costs, stringent regulatory requirements, and the prevalence of generic alternatives dampening brand-name revenues. Additionally, patient compliance issues due to complex treatment regimens present hurdles. To capitalize on growth, firms could innovate in areas such as digital health solutions that ensure better patient adherence through reminders and real-time monitoring, or invest in R&D for more efficient inhaler mechanisms. Collaboration with tech companies could enhance treatment personalization and data-based insights into patient response patterns. Despite the competitive landscape, a focus on affordable and accessible treatments, along with strategic partnerships focusing on R&D and distribution, can provide a sustained competitive edge and foster market expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 296.81 million
Estimated Year [2024] USD 309.72 million
Forecast Year [2030] USD 400.77 million
CAGR (%) 4.38%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bronchial Spasms Treatment Market

The Bronchial Spasms Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of asthma and COPD globally
    • Increasing government spending and healthcare initiatives
    • Growing awareness regarding bronchial spasms and their impact on health
  • Market Restraints
    • High costs associated with treatment and stringent regulations regarding the release of drugs
  • Market Opportunities
    • Strategic partnerships between pharma companies and research institutions
    • Innovations in inhaler devices, nebulizers, and bronchial spasm treatment
  • Market Challenges
    • Adverse effects associated with bronchial spasms treatments

Porter's Five Forces: A Strategic Tool for Navigating the Bronchial Spasms Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bronchial Spasms Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bronchial Spasms Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bronchial Spasms Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bronchial Spasms Treatment Market

A detailed market share analysis in the Bronchial Spasms Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bronchial Spasms Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bronchial Spasms Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bronchial Spasms Treatment Market

A strategic analysis of the Bronchial Spasms Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bronchial Spasms Treatment Market, highlighting leading vendors and their innovative profiles. These include Amphastar Pharmaceuticals, Inc, Bayer AG, C.H. Boehringer Sohn AG & Co. KG, CHIESI Farmaceutici S.p.A., Cipla Limited, GlaxoSmithKline plc, Grifols, S.A., Lybrate, Inc., Merck KGaA, Novartis AG, Orion Corporation, Pfizer Inc, Temple University Health System, Inc., Teva Pharmaceutical Industries Ltd, Vectura Group Ltd by Philip Morris International Inc., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Bronchial Spasms Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Medications and Non-Pharmacological Treatments. The Medications is further studied across Bronchodilators, Corticosteroids, Leukotriene Modifiers, Mast Cell Stabilizers, and Methylxanthines. The Non-Pharmacological Treatments is further studied across Oxygen Therapy and Pulmonary Rehabilitation.
  • Based on Route of Administration, market is studied across Inhalation, Intravenous, Oral, and Subcutaneous.
  • Based on End User, market is studied across Ambulatory Surgical Centers, Homecare Settings, Hospitals & Clinics, and Research & Academic Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of asthma and COPD globally
      • 5.1.1.2. Increasing government spending and healthcare initiatives
      • 5.1.1.3. Growing awareness regarding bronchial spasms and their impact on health
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with treatment and stringent regulations regarding the release of drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Strategic partnerships between pharma companies and research institutions
      • 5.1.3.2. Innovations in inhaler devices, nebulizers, and bronchial spasm treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effects associated with bronchial spasms treatments
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type: Rising usage of medications for immediate relief and long-term management to improve patient quality of life
    • 5.2.2. End User: Consumer preference for homecare settings due to convenience and ease of maintenance
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bronchial Spasms Treatment Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Medications
    • 6.2.1. Bronchodilators
    • 6.2.2. Corticosteroids
    • 6.2.3. Leukotriene Modifiers
    • 6.2.4. Mast Cell Stabilizers
    • 6.2.5. Methylxanthines
  • 6.3. Non-Pharmacological Treatments
    • 6.3.1. Oxygen Therapy
    • 6.3.2. Pulmonary Rehabilitation

7. Bronchial Spasms Treatment Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Inhalation
  • 7.3. Intravenous
  • 7.4. Oral
  • 7.5. Subcutaneous

8. Bronchial Spasms Treatment Market, by End User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Homecare Settings
  • 8.4. Hospitals & Clinics
  • 8.5. Research & Academic Institutes

9. Americas Bronchial Spasms Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Bronchial Spasms Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Bronchial Spasms Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Verona Pharma ohtuvayre gains FDA approval as first novel inhaled COPD treatment
    • 12.3.2. Viatris and Kindeva launch FDA-approved generic Symbicort, Breyna, to enhance asthma and COPD treatment accessibility
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amphastar Pharmaceuticals, Inc
  • 2. Bayer AG
  • 3. C.H. Boehringer Sohn AG & Co. KG
  • 4. CHIESI Farmaceutici S.p.A.
  • 5. Cipla Limited
  • 6. GlaxoSmithKline plc
  • 7. Grifols, S.A.
  • 8. Lybrate, Inc.
  • 9. Merck KGaA
  • 10. Novartis AG
  • 11. Orion Corporation
  • 12. Pfizer Inc
  • 13. Temple University Health System, Inc.
  • 14. Teva Pharmaceutical Industries Ltd
  • 15. Vectura Group Ltd by Philip Morris International Inc.
  • 16. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. BRONCHIAL SPASMS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. BRONCHIAL SPASMS TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. BRONCHIAL SPASMS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. BRONCHIAL SPASMS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BRONCHIAL SPASMS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BRONCHIAL SPASMS TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MAST CELL STABILIZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY METHYLXANTHINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY OXYGEN THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY PULMONARY REHABILITATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 238. BRONCHIAL SPASMS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 239. BRONCHIAL SPASMS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023